Biofrontera Has Yet to Confirm Third-Quarter Results; Report Scheduled for November 30
Key Facts
It could not be verified that Biofrontera’s revenue rose 30% in the third quarter of 2026 or that its losses exceeded analysts’ expectations, as the cited Investing.com page could not be opened and no reliable disclosure confirming the two figures was found. The company’s financial calendar lists November 30, 2026, as the release date for its third-quarter report. Until the report is released, the quarter’s figures cannot be confirmed or compared with market estimates based on the information available here. Company data for the first half point to growth in European sales and improvement in some operating indicators, but they relate to an earlier period and do not establish third-quarter performance. Biofrontera AG, the German company, should also be distinguished from the U.S. company Biofrontera Inc., as published data for each relate to different metrics and periods.
Biofrontera AG said revenue from European sales rose 44.3% to 9.0 million euros in the first half of 2026 compared with the first half of 2025. The company attributed part of the increase to temporary wholesaler stocking in Germany ahead of an Ameluz price increase in July. Management said the effects of the temporary stocking were expected to unwind over the following months as inventories returned to normal levels. Accordingly, part of the European sales growth was linked to distributors’ purchasing timing, according to the company’s explanation, and alone does not show that the same pace continued in later periods. These figures relate to Biofrontera AG and its European sales; they should not be combined with the U.S. company’s results or treated as third-quarter figures.
On liquidity, Biofrontera AG said cash and cash equivalents totaled 7.1 million euros on June 30, 2026, compared with 3.6 million euros at the end of 2025. This reflects an increase in the cash balance between the two dates reported by the company as part of its first-half data. It also said adjusted earnings before interest, taxes, depreciation and amortization from continuing operations turned positive at 1.7 million euros in the first half of 2026, from negative 1.3 million euros in the year-earlier period. The two indicators provide context on the company’s position during the first six months, but they do not determine the result for the quarter ended in September or establish whether analysts’ expectations were met or exceeded.
Biofrontera Inc. reported net product revenue of 12.0 million dollars in the second quarter of 2026, up 32.9% from 9.0 million dollars in the same period a year earlier. Gross margin rose to 80% from 71%, an improvement of about 920 basis points, and the company said lower Ameluz costs following the strategic transaction contributed to the improvement. Its net loss also narrowed to 0.6 million dollars, or 0.05 dollars per share, compared with a loss of 5.3 million dollars, or 0.57 dollars per share, in the second quarter of 2025. These results relate to the U.S. company and the second quarter, and therefore do not confirm the claim of Biofrontera revenue growth in the third quarter or widening losses.
Biofrontera AG issued fiscal 2026 revenue guidance in March in a range of 14 to 16 million euros. This range relates to the German company AG, not the U.S. company Inc. The quarterly report date listed on Biofrontera AG’s calendar is November 30, 2026, when the company is scheduled to publish its third-quarter figures. Until then, claims of 30% revenue growth and losses wider than expected remain unconfirmed by the available evidence.